Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• "No go" donor hepatectomy in living-donor liver transplantation.1 passage
• 'First week' is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure.1 passage
• A brief review on prognostic models of primary biliary cholangitis.1 passage
• A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.1 passage
• A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry.1 passage
• A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China.1 passage
• A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis.1 passage
• A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion.1 passage
• A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.1 passage
• A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir.1 passage
• A novel radiomics-platelet nomogram for the prediction of gastroesophageal varices needing treatment in cirrhotic patients.1 passage
• A novel, bedside, etiology specific prognostic model (Peds-HAV) in hepatitis A induced pediatric acute liver failure.1 passage
• A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.1 passage
• A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes.1 passage
• A proposed pathologic sub-classification of drug-induced liver injury.1 passage
• A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment.1 passage
• A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan.1 passage
• A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C.1 passage
• A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC.1 passage
• A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat?1 passage
• AARC-ACLF score: best predictor of outcome in children and adolescents with decompensated Wilson disease.1 passage
• AKI in patients with acute on chronic liver failure is different from acute decompensation of cirrhosis.1 passage
• AKI persistence at 48 h predicts mortality in patients with acute on chronic liver failure.1 passage
• APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.1 passage
• APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.1 passage
• APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?1 passage
• APASL consensus statements and recommendation on treatment of hepatitis C.1 passage
• APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.1 passage
• APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.1 passage
• APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19.1 passage
• Accuracy of contrast-enhanced ultrasound liver imaging reporting and data system: a systematic review and meta-analysis.1 passage
• Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.1 passage
• Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study.1 passage
• Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China.1 passage
• Acute kidney injury in acute on chronic liver failure.1 passage
• Acute kidney injury in hepatitis B-related acute-on-chronic liver failure without preexisting liver cirrhosis.1 passage
• Acute kidney injury: prediction, prognostication and optimisation for liver transplant.1 passage
• Acute liver failure in Budd-Chiari syndrome and a model to predict mortality.1 passage
• Acute rejection after liver transplantation is less common, but predicts better prognosis in HBV-related hepatocellular carcinoma patients.1 passage
• Acute variceal bleeding: risk stratification and management (including TIPS).1 passage
• Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.1 passage
• Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection.1 passage
• Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.1 passage
• Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort.1 passage
• Advances in the management of HIV/HCV coinfection.1 passage
• Advances in therapeutics for chronic hepatitis B.1 passage
• Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis.1 passage
• Albumin in chronic liver disease: structure, functions and therapeutic implications.1 passage
• Algorithms for managing coagulation disorders in liver disease.1 passage
• Aligning to the sample-specific reference sequence to optimize the accuracy of next-generation sequencing analysis for hepatitis B virus.1 passage
• Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.1 passage
• Alterations of gut microbiome and metabolite profiles in choledocholithiasis concurrent with cholangitis.1 passage
• Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis.1 passage
• An imbalance between stellate cells and γδT cells contributes to hepatocellular carcinoma aggressiveness and recurrence.1 passage
• An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients.1 passage
• Analysis of adult 20-year survivors after liver transplantation.1 passage
• Analysis of the high incidence of acute kidney injury associated with acute-on-chronic liver failure.1 passage
• Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study).1 passage
• Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure.1 passage
• Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis.1 passage
• Antifibrotics in liver disease: are we getting closer to clinical use?1 passage
• Antimicrobial resistance in chronic liver disease.1 passage
• Application of the BAR score as a predictor of short- and long-term survival in liver transplantation patients.1 passage
• Applied precision cancer medicine in metastatic biliary tract cancer.1 passage
• Approach and management of dysnatremias in cirrhosis.1 passage
• Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma.1 passage
• Ascitic fluid infection in children with liver disease: time to change empirical antibiotic policy.1 passage
• Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.1 passage
• Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.1 passage
• Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.1 passage
• Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.1 passage
• Assessment of liver fibrosis by transient elastography in young children with chronic hepatitis B virus infection.1 passage
• Association between hepatitis B virus basal core promoter/precore region mutations and the risk of hepatitis B-related acute-on-chronic liver failure in the Chinese population: an updated meta-analysis.1 passage
• Association between neutrophil-lymphocyte ratio, socioeconomic status, and ethnic minority with treatment outcome in hepatocellular carcinoma.1 passage
• Association between retinal artery lesions and nonalcoholic fatty liver disease.1 passage
• Association of SIRT1 gene polymorphism and its expression for the risk of alcoholic fatty liver disease in the Han population.1 passage
• Association of adiponectin gene polymorphisms and additional gene-gene interaction with nonalcoholic fatty liver disease in the Chinese Han population.1 passage
• Association of arterial stiffness with the histological severity of nonalcoholic fatty liver disease.1 passage
• Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis.1 passage
• Association of the Laennec staging system with degree of cirrhosis, clinical stage and liver function.1 passage
• Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?1 passage
• Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016.1 passage
• Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis.1 passage
• Balloon-occluded retrograde transvenous obliteration of varices: focusing on the portal hemodynamics and the recent techniques.1 passage
• Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study.1 passage
• Beyond KCH selection and options in acute liver failure.1 passage
• Bi-lobar liver biopsy via EUS enhances the assessment of disease severity in patients with non-alcoholic steatohepatitis.1 passage
• Bile acids: emerging role in management of liver diseases.1 passage
• Bile extracellular vesicles from end-stage liver disease patients show altered microRNA content.1 passage
• Biliary complications in right lobe living donor liver transplantation.1 passage
• Biliary features in liver histology of children with autoimmune liver disease.1 passage
• Biology of portal hypertension.1 passage
• Budd-Chiari syndrome has different presentations and disease severity during adolescence.1 passage
• Budd-Chiari syndrome/hepatic venous outflow tract obstruction.1 passage
• Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).1 passage
• C1QTNF1-AS1 regulates the occurrence and development of hepatocellular carcinoma by regulating miR-221-3p/SOCS3.1 passage
• CCL15 overexpression predicts poor prognosis for hepatocellular carcinoma.1 passage
• CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma.1 passage
• CSH guidelines for the diagnosis and treatment of drug-induced liver injury.1 passage
• Cardiac abnormalities in cirrhotic children: pre- and post-liver transplantation.1 passage
• Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT.1 passage
• Cell cycle regulation in NAFLD: when imbalanced metabolism limits cell division.1 passage
• Cellular and functional loss of liver endothelial cells correlates with poor hepatocyte regeneration in acute-on-chronic liver failure.1 passage
• Characteristics and outcome of autoimmune liver disease in Asian children.1 passage
• Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.1 passage
• Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease.1 passage
• Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients.1 passage
• Chinese guidelines on the management of ascites and its related complications in cirrhosis.1 passage
• Chronic hepatitis B: the demise of the 'inactive carrier' phase.1 passage
• Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study.1 passage
• Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait.1 passage
• Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection.1 passage
• Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.1 passage
• Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China.1 passage
• Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China.1 passage
• Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.1 passage
• Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges.1 passage
• Clinical implication and viral mutation in basal core promoter/pre-core of hepatitis B virus C/D recombinant.1 passage
• Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma.1 passage
• Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations.1 passage
• Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection.1 passage
• Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma.1 passage
• Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm.1 passage
• Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.1 passage
• Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients.1 passage
• Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.1 passage
• Comparable short- and long-term outcomes in deceased-donor and living-donor liver retransplantation.1 passage
• Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF.1 passage
• Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease.1 passage
• Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial.1 passage
• Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy.1 passage
• Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B.1 passage
• Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI.1 passage
• Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region.1 passage
• Consensus on the secondary prevention of primary liver cancer.1 passage
• Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases.1 passage
• Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.1 passage
• Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis.1 passage
• Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India.1 passage
• Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection.1 passage
• Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.1 passage
• Criteria for liver transplantation in ACLF and outcome.1 passage
• Current perspectives on the tumor microenvironment in hepatocellular carcinoma.1 passage
• Current progress in host innate and adaptive immunity against hepatitis C virus infection.1 passage
• Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology.1 passage
• DAMPs and sterile inflammation in drug hepatotoxicity.1 passage
• Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.1 passage
• Definition of ACLF and inclusion criteria for extra-hepatic organ failure.1 passage
• Depression, fatigue and neurocognitive deficits in chronic hepatitis C.1 passage
• Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies.1 passage
• Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery.1 passage
• Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease.1 passage
• Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study.1 passage
• Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers.1 passage
• Diabetes is associated with poor short-term prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure.1 passage
• Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis.1 passage
• Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients.1 passage
• Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.1 passage
• Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study.1 passage
• Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium.1 passage
• Distribution and clinical relevance of phospholipids in hepatocellular carcinoma.1 passage
• Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?1 passage
• Double-blind placebo-controlled randomized trial of N-acetylcysteine infusion following live donor liver transplantation.1 passage
• Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.1 passage
• Dynamic Optic Nerve Sheath Diameter (ONSD) guided management of raised intracranial pressure in pediatric acute liver failure.1 passage
• Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure.1 passage
• Dynamic changes of T cell receptor repertoires in patients with hepatitis B virus-related acute-on-chronic liver failure.1 passage
• Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response.1 passage
• Effect of COVID-19 on patients with compensated chronic liver diseases.1 passage
• Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation.1 passage
• Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation.1 passage
• Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis.1 passage
• Effect of endoscopic variceal obliteration by band ligation on portal hypertensive gastro-duodenopathy: endoscopic and pathological study.1 passage
• Effect of hepatitis B surface antibody in patients with core antibody-positive liver transplantation: a systematic review and meta-analysis.1 passage
• Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease.1 passage
• Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection.1 passage
• Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.1 passage
• Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma.1 passage
• Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan.1 passage
• Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.1 passage
• Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis.1 passage
• Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.1 passage
• Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.1 passage
• Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.1 passage
• Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.1 passage
• Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.1 passage
• Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding.1 passage
• Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.1 passage
• Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.1 passage
• Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis.1 passage
• Efficacy of peg-interferon-nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB.1 passage
• Efficacy of vasopressin/terlipressin and somatostatin/octreotide for the prevention of early variceal rebleeding after the initial control of bleeding: a systematic review and meta-analysis.1 passage
• Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection.1 passage
• Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis.1 passage
• End-points for drug treatment in NASH.1 passage
• End-stage liver disease patients with MELD >40 have higher waitlist mortality compared to Status 1A patients.1 passage
• Endoscopic treatments for portal hypertension.1 passage
• Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis.1 passage
• Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus.1 passage
• Enhanced efficacy of radiofrequency ablation for hepatocellular carcinoma using a novel vascular disrupting agent, CKD-516.1 passage
• Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial.1 passage
• Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.1 passage
• Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis.1 passage
• Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.1 passage
• Essential components in developing public policy to control viral hepatitis: lessons from Taiwan.1 passage
• Establishment and validation of a prognostic model for hepatitis B virus‑related acute-on-chronic liver failure patients with bacterial infection.1 passage
• Establishment of a murine model of acute-on-chronic liver failure with multi-organ dysfunction.1 passage
• Evaluation of liver function using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging based on a three-dimensional volumetric analysis system.1 passage
• Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial.1 passage
• Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry.1 passage
• Existence of cancer stem cells in hepatocellular carcinoma: myth or reality?1 passage
• Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population.1 passage
• FTY720, a sphingosine-1-phosphate (S1P) receptor modulator, protects sinusoid endothelial cells from radiation injury in vitro.1 passage
• Factors associated with major radiological progression of primary sclerosing cholangitis in patients with inflammatory bowel disease.1 passage
• Feasibility of liver graft procurement with donor gallbladder preservation in living donor liver transplantation.1 passage
• Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.1 passage
• Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools.1 passage
• Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift.1 passage
• First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients.1 passage
• Functional restoration of CD561 passage
• Functionality of beta-adrenergic receptors in patients with cirrhosis treated chronically with non-selective beta-blockers.1 passage
• Functionally aberrant dendritic cell subsets and expression of DC-SIGN differentiate acute from chronic HBV infection.1 passage
• Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9-12 years) and adolescents.1 passage
• Genetic and epigenetic mechanisms of NASH.1 passage
• Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.1 passage
• Global HBV burden: guesstimates and facts.1 passage
• Glucose fluctuations reduce quality of sleep and of life in patients with liver cirrhosis.1 passage
• Goals and targets for personalized therapy for HCC.1 passage
• Gross type of hepatocellular carcinoma reflects the tumor hypoxia, fibrosis, and stemness-related marker expression.1 passage
• Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.1 passage
• HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.1 passage
• HBV culture and infectious systems.1 passage
• HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea.1 passage
• HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes.1 passage
• HBx promotes hepatocarcinogenesis by enhancing phosphorylation and blocking ubiquitinylation of UHRF2.1 passage
• HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort.1 passage
• HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b.1 passage
• HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.1 passage
• HCV management in resource-constrained countries.1 passage
• Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis.1 passage
• Hepatic encephalopathy in acute-on-chronic liver failure.1 passage
• Hepatic encephalopathy: a critical current review.1 passage
• Hepatic fibrosis is associated with an increased rate of decline in bone mineral density in men with nonalcoholic fatty liver disease.1 passage
• Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.1 passage
• Hepatic stellate cells: fibrogenic, regenerative or both? Heterogeneity and context are key.1 passage
• Hepatic tuberculosis masquerading as malignancy.1 passage
• Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression.1 passage
• Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia.1 passage
• Hepatitis B virus infection and diabetes mellitus: the Kailuan prospective cohort study in China.1 passage
• Hepatitis B virus infection in children of HBV-related chronic liver disease patients: a study of intra-familial HBV transmission.1 passage
• Hepatitis B virus receptors and molecular drug targets.1 passage
• Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread.1 passage
• Hepatitis C genotype 3 disease.1 passage
• Hepatitis C virus as a systemic disease: reaching beyond the liver.1 passage
• Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.1 passage
• Hepatocellular carcinoma and non-alcoholic fatty liver disease.1 passage
• Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis.1 passage
• Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure.1 passage
• Hepatocyte-like cells derived from induced pluripotent stem cells.1 passage
• Hepatology through the crystal ball.1 passage
• Hepatopulmonary syndrome is related to the development of acute-on-chronic liver failure and poor prognosis in cirrhotic patients.1 passage
• Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury.1 passage
• High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease.1 passage
• High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study.1 passage
• High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy.1 passage
• High rate of core promoter and precore mutations in patients with chronic hepatitis B.1 passage
• High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.1 passage
• High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.1 passage
• Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease.1 passage
• How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?1 passage
• How to achieve immune control in chronic hepatitis B?1 passage
• How to identify the need for liver transplantation in pediatric acute-on-chronic liver failure?1 passage
• Human fascioliasis presenting as liver abscess: clinical characteristics and management.1 passage
• Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back.1 passage
• Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise.1 passage
• Identification and validation of a prognostic four-genes signature for hepatocellular carcinoma: integrated ceRNA network analysis.1 passage
• Identification of prognostic claudins signature in hepatocellular carcinoma from a hepatocyte differentiation model.1 passage
• Identifying barriers to treatment of HCV in the primary care setting.1 passage
• Idiopathic portal hypertension and extrahepatic portal venous obstruction.1 passage
• Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders.1 passage
• Immune checkpoint receptors: homeostatic regulators of immunity.1 passage
• Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction.1 passage
• Immunological cure of HBV infection.1 passage
• Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.1 passage
• Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group.1 passage
• Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.1 passage
• Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.1 passage
• Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure.1 passage
• Impact of etiological treatment on prognosis.1 passage
• Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study.1 passage
• Impact of propofol sedation on the diagnostic accuracy of hepatic venous pressure gradient measurements in patients with cirrhosis.1 passage
• Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.1 passage
• Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis.1 passage
• Implications of liver injury in risk-stratification and management of patients with COVID-19.1 passage
• Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope technology.1 passage
• Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients.1 passage
• Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis.1 passage
• Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis.1 passage
• Increased risk of cancer in patients with primary sclerosing cholangitis.1 passage
• Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians.1 passage
• Influence of proton pump inhibitors on microbiota in chronic liver disease patients.1 passage
• Influence of variceal bleeding on natural history of ACLF and management options.1 passage
• Interferon gamma, interleukin-6, and -17a levels were correlated with minimal hepatic encephalopathy in HBV patients.1 passage
• Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.1 passage
• Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C.1 passage
• Interleukin-22 in alcoholic hepatitis and beyond.1 passage
• Intestinal failure-associated liver disease (IFALD): insights into pathogenesis and advances in management.1 passage
• Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma.1 passage
• Invasive and non-invasive assessment of portal hypertension.1 passage
• Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma.1 passage
• Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment.1 passage
• Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?1 passage
• Laser capture microdissection: techniques and applications in liver diseases.1 passage
• Late liver function test abnormalities post-adult liver transplantation: a review of the etiology, investigation, and management.1 passage
• Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka.1 passage
• Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.1 passage
• Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant.1 passage
• Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.1 passage
• Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells.1 passage
• Lipid profiles of donors and recipients of liver transplant: like father like son.1 passage
• Live donor liver transplantation for alcoholic hepatitis.1 passage
• Liver cirrhosis and cancer: comparison of mortality.1 passage
• Liver damage favors the eliminations of HBV integration and clonal hepatocytes in chronic hepatitis B.1 passage
• Liver damage related to immune checkpoint inhibitors.1 passage
• Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools.1 passage
• Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models.1 passage
• Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease.1 passage
• Liver injury in patients with COVID-19: clinical profiles, CT findings, the correlation of the severity with liver injury.1 passage
• Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil.1 passage
• Liver organoids reproduce alpha-1 antitrypsin deficiency-related liver disease.1 passage
• Liver progenitor cells-mediated liver regeneration in liver cirrhosis.1 passage
• Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.1 passage
• Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI).1 passage
• Liver transplantation in acute on chronic liver failure: challenges and an algorithm for patient selection and management.1 passage
• Liver transplantation in acute-on-chronic liver failure: lessons learnt from acute liver failure setting.1 passage
• Living donor liver transplant (LDLT) is the way forward in Asia.1 passage
• Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years.1 passage
• Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results.1 passage
• Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.1 passage
• Long-term observation of acute-onset autoimmune hepatitis presenting clinically and radiologically as acute hepatitis.1 passage
• Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).1 passage
• Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.1 passage
• Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.1 passage
• Longitudinal progression of clinical variables associated with graded liver injury in COVID-19 patients.1 passage
• Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.1 passage
• Low expression of N-myc downstream-regulated gene 2 (NDRG2) correlates with poor prognosis in hepatoblastoma.1 passage
• Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis.1 passage
• Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib.1 passage
• Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer.1 passage
• Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys.1 passage
• Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.1 passage
• Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?1 passage
• Management of acute-on-chronic liver failure: an algorithmic approach.1 passage
• Management of ascites and hepatorenal syndrome.1 passage
• Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review.1 passage
• Management of post transplant hepatitis C in the direct antiviral agents era.1 passage
• Management of primary sclerosing cholangitis and its complications: an algorithmic approach.1 passage
• Maternal-fetal outcome in pregnancies complicated with non-cirrhotic portal hypertension: experience from a Tertiary Centre in South India.1 passage
• Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial.1 passage
• Metabolic effects of reduced growth hormone action in fatty liver disease.1 passage
• Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study.1 passage
• Metal, magnet or transplant: options in primary sclerosing cholangitis with stricture.1 passage
• MicroRNA-744/transforming growth factor β1 relationship regulates liver cirrhosis.1 passage
• Microalbuminuria, systemic inflammation, and multiorgan dysfunction in decompensated cirrhosis: evidence for a nonfunctional mechanism of hepatorenal syndrome.1 passage
• Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study.1 passage
• Model for end-stage liver disease score and MELD exceptions: 15 years later.1 passage
• Models for acute on chronic liver failure development and mortality in a veterans affairs cohort.1 passage
• Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy.1 passage
• Molecular mechanisms of HBeAg in persistent HBV infection.1 passage
• Mother-to-infant transmission of hepatitis B virus: challenges and perspectives.1 passage
• Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study.1 passage
• Multiple genes identified as targets for 20q13.12-13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma.1 passage
• Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin.1 passage
• Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis.1 passage
• National trends of acute kidney injury requiring dialysis in decompensated cirrhosis hospitalizations in the United States.1 passage
• Natural history of large regenerative nodules and dysplastic nodules in liver cirrhosis: 28-year follow-up study.1 passage
• Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy.1 passage
• Neonatal hepatitis B vaccination protects mature adults from occult virus infection.1 passage
• New approaches for fibrosis regression in alcoholic cirrhosis.1 passage
• New cellular and molecular targets for the treatment of portal hypertension.1 passage
• New concepts on the clinical course and stratification of compensated and decompensated cirrhosis.1 passage
• New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan.1 passage
• New drugs for NAFLD: lessons from basic models to the clinic.1 passage
• New paradigms in management of alcoholic hepatitis: a review.1 passage
• New therapeutic targets in alcoholic hepatitis.1 passage
• Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke.1 passage
• Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.1 passage
• Non-invasive assessment of portal hypertension and liver fibrosis using contrast-enhanced ultrasonography.1 passage
• Non-invasive diagnosis of hepatic steatosis.1 passage
• Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis.1 passage
• Noninvasive assessment of liver fibrosis for predicting acute-on-chronic liver failure in patients with chronic hepatitis B.1 passage
• Noninvasive chimeric DNA profiling identifies tumor-originated HBV integrants contributing to viral antigen expression in liver cancer.1 passage
• Noninvasive serum models to predict significant liver related events in chronic hepatitis C.1 passage
• Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis.1 passage
• Novel insights in preventing Gram-negative bacterial infection in cirrhotic patients: review on the effects of GM-CSF in maintaining homeostasis of the immune system.1 passage
• Novel systemic therapy for hepatocellular carcinoma.1 passage
• Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.1 passage
• Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficacious.1 passage
• Obstructive sleep apnea is an important predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease in a tertiary care center.1 passage
• One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.1 passage
• Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan.1 passage
• Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial.1 passage
• Pattern and profile of chronic liver disease in acute on chronic liver failure.1 passage
• Pediatric non-cirrhotic portal fibrosis: role of endoscopic management in determining long-term outcome.1 passage
• Pegylated-interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non-cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open-label pilot trial.1 passage
• Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival.1 passage
• Performance of transient elastography assessing fibrosis of single hepatitis B virus infection: a systematic review and meta-analysis of a diagnostic test.1 passage
• Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide.1 passage
• Pharmacologic prevention of variceal bleeding and rebleeding.1 passage
• Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.1 passage
• Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT.1 passage
• Plasma perfusion combined with plasma exchange in chronic hepatitis B-related acute-on-chronic liver failure patients.1 passage
• Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms.1 passage
• Platelets' increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis.1 passage
• Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease.1 passage
• Pokemon promotes the invasiveness of hepatocellular carcinoma by enhancing MEF2D transcription.1 passage
• Portal inflammation predicts renal dysfunction in patients with nonalcoholic fatty liver disease.1 passage
• Portal vein thrombosis associated with high 14-day and 6-week rebleeding in patients after oesophageal variceal band ligation: a retrospective, multicentre, nested case-control study.1 passage
• Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals.1 passage
• Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).1 passage
• Precise fibrosis staging with shear wave elastography in chronic hepatitis B depends on liver inflammation and steatosis.1 passage
• Precision-cut liver slices: a versatile tool to advance liver research.1 passage
• Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis.1 passage
• Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease.1 passage
• Predicting the available space for liver transplantation in cirrhotic patients: a computed tomography-based volumetric study.1 passage
• Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers.1 passage
• Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.1 passage
• Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study.1 passage
• Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.1 passage
• Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin.1 passage
• Prednisolone plus S-adenosil-L-methionine in severe alcoholic hepatitis.1 passage
• Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.1 passage
• Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.1 passage
• Prevalence and risk factors of erectile dysfunction in patients with liver cirrhosis: a systematic review and meta-analysis.1 passage
• Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis.1 passage
• Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population: a retrospective study of incidental liver biopsies.1 passage
• Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study.1 passage
• Prevention and management of hepatitis B virus reactivation in cancer patients.1 passage
• Prevention of hepatitis B virus-associated liver diseases by antiviral therapy.1 passage
• Primary biliary cholangitis: a comprehensive overview.1 passage
• Primary prophylaxis of gastric variceal bleeding: endoscopic obturation, radiologic intervention, or observation?1 passage
• Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis.1 passage
• Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.1 passage
• Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach.1 passage
• Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.1 passage
• Psychiatric comorbidities among patients undergoing liver transplantation in South Korea: a nationwide population-based study.1 passage
• Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016.1 passage
• Radiomics in hepatocellular carcinoma: a quantitative review.1 passage
• Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study.1 passage
• Recent advances in hemochromatosis: a 2015 update : a summary of proceedings of the 2014 conference held under the auspices of Hemochromatosis Australia.1 passage
• Red cell distribution width to platelet ratio, a useful indicator of liver fibrosis in chronic hepatitis patients.1 passage
• Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.1 passage
• Regression of portal hypertension: underlying mechanisms and therapeutic strategies.1 passage
• Reimbursement policies in the Asia-Pacific for chronic hepatitis B.1 passage
• Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis.1 passage
• Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review.1 passage
• Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease.1 passage
• Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.1 passage
• Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma.1 passage
• Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.1 passage
• Reversal of NASH fibrosis with pharmacotherapy.1 passage
• Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study.1 passage
• Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt.1 passage
• Risk factors of poor prognosis in patients with pyrrolidine alkaloids induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt : Transjugular intrahepatic portosystemic shunt in patients with sinusoidal obstruction syndrome, etiology matters.1 passage
• Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.1 passage
• Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines.1 passage
• Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan.1 passage
• Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.1 passage
• Role of cytokine gene polymorphisms in acute and chronic kidney disease following liver transplantation.1 passage
• Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection.1 passage
• Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.1 passage
• S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma.1 passage
• SHG/TPEF-based image technology improves liver fibrosis assessment of minimally sized needle biopsies.1 passage
• Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.1 passage
• Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B.1 passage
• Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects.1 passage
• Sarcopenia and fatty liver disease.1 passage
• Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.1 passage
• Second primary cancer after liver transplantation in hepatocellular carcinoma: a nationwide population-based study.1 passage
• Selection and outcome of the potential live liver donor.1 passage
• Sepsis in cirrhosis: emerging concepts in pathogenesis, diagnosis and management.1 passage
• Sepsis-induced acute kidney injury in patients with cirrhosis.1 passage
• Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study.1 passage
• Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.1 passage
• Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population.1 passage
• Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease.1 passage
• Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis.1 passage
• Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study.1 passage
• Silencing of functional p53 attenuates NAFLD by promoting HMGB1-related autophagy induction.1 passage
• Single-nucleotide rs738409 polymorphisms in the PNPLA3 gene are strongly associated with alcoholic liver disease in Han Chinese males.1 passage
• Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.1 passage
• Sofosbuvir for treatment of chronic hepatitis C.1 passage
• Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.1 passage
• Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.1 passage
• Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.1 passage
• Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan.1 passage
• Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.1 passage
• Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.1 passage
• Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation.1 passage
• Spectrum of histopathological changes in patients with non-cirrhotic portal fibrosis.1 passage
• Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients.1 passage
• Spontaneous bacteremia and spontaneous bacterial peritonitis in cirrhosis: two infections but similar outcomes?1 passage
• Spontaneous bacteremia and spontaneous bacterial peritonitis share similar prognosis in patients with cirrhosis: a cohort study.1 passage
• Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance.1 passage
• Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis.1 passage
• Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.1 passage
• Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.1 passage
• Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers.1 passage
• Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data.1 passage
• Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.1 passage
• Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis.1 passage
• Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial.1 passage
• Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.1 passage
• Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.1 passage
• Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis.1 passage
• Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment.1 passage
• Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.1 passage
• The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.1 passage
• The arterial tumor enhancement pattern on contrast-enhanced computed tomography is associated with primary cancer death after radiofrequency ablation for small hepatocellular carcinoma.1 passage
• The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015.1 passage
• The characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patients.1 passage
• The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes.1 passage
• The dynamic changes of circulating invariant natural killer T cells during chronic hepatitis B virus infection.1 passage
• The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure.1 passage
• The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.1 passage
• The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.1 passage
• The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.1 passage
• The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040.1 passage
• The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis.1 passage
• The global trends and regional differences in incidence and mortality of hepatitis A from 1990 to 2019 and implications for its prevention.1 passage
• The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.1 passage
• The impact of metabolic syndrome and prevalent liver disease on living donor liver transplantation: a pressing need to expand the pool.1 passage
• The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan.1 passage
• The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study.1 passage
• The metabolic profiles and body composition of lean metabolic associated fatty liver disease.1 passage
• The overview of the deep learning integrated into the medical imaging of liver: a review.1 passage
• The portal hypertension syndrome: etiology, classification, relevance, and animal models.1 passage
• The potential role of liver stem cells in initiation of primary liver cancer.1 passage
• The preS deletion of hepatitis B virus (HBV) is associated with liver fibrosis progression in patients with chronic HBV infection.1 passage
• The predictors of post-transplant coronary events among liver transplant recipients.1 passage
• The prevalence of occult HBV infection in immunized children with HBsAg-positive parents: a hospital-based analysis.1 passage
• The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis.1 passage
• The role of bile salts in liver regeneration.1 passage
• The role of neutrophils in innate immunity-driven nonalcoholic steatohepatitis: lessons learned and future promise.1 passage
• The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.1 passage
• Therapeutic implications of granulocyte colony stimulating factor in patients with acute-on-chronic liver failure: increased survival and containment of liver damage.1 passage
• Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype.1 passage
• Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension.1 passage
• Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China.1 passage
• Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study).1 passage
• Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.1 passage
• Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients.1 passage
• Transjugular intrahepatic portosystemic shunt in liver transplant recipients: indications, feasibility, and outcomes.1 passage
• Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis.1 passage
• Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.1 passage
• Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial.1 passage
• Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort).1 passage
• Tsumura-Suzuki obese diabetic mice-derived hepatic tumors closely resemble human hepatocellular carcinomas in metabolism-related genes expression and bile acid accumulation.1 passage
• Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.1 passage
• Twenty-year survival post-liver transplant: challenges and lessons.1 passage
• Twist in hepatocellular carcinoma: pathophysiology and therapeutics.1 passage
• Urine albumin-to-creatinine ratio is associated with the severity of liver disease, renal function and survival in patients with decompensated cirrhosis.1 passage
• Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B.1 passage
• Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis.1 passage
• Utility of N-acetylcysteine in ischemic hepatitis in cirrhotics with acute variceal bleed: a randomized controlled trial.1 passage
• Viral factors for HBV mother-to-child transmission.1 passage
• Virus-induced hepatocellular carcinoma with special emphasis on HBV.1 passage
• Viscoelastic test-based bleeding risk score reliably predicts coagulopathic bleeding in decompensated cirrhosis and ACLF patients.1 passage
• Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis.1 passage
• Volumetric assessment and clinical predictors of cirrhosis in patients undergoing hepatectomy for hepatocellular carcinoma with presumed normal liver function.1 passage
• Weight fluctuation and risk of hepatocellular carcinoma: a nationwide population-based 8-million-subject study.1 passage
• Will a second biopsy sample affect treatment decisions in patients with chronic hepatitis B?1 passage
• Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.1 passage
• β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children.1 passage